⏳ Final hours! Save up to 60% OFF InvestingProCLAIM SALE

Novo Nordisk hits record highs as study shows Wegovy treatment cut the risk of heart issues by 20%

Published 08/08/2023, 06:41 AM
Updated 08/08/2023, 06:42 AM
©  Reuters Novo Nordisk (NVO) hits record highs as study shows Wegovy treatment cut the risk of heart issues by 20%
LLY
-
NVO
-

Obesity drug maker Novo Nordisk (NYSE:NVO) shares rose as much as 10% in pre-market Tuesday to hit new record highs after the company said its Wegovy treatment cut the risk of heart issues by 20% in a select trial.

Shares in the rival Eli Lilly (NYSE:LLY) surged nearly 7% on the update with the company expected to report its second-quarter results before the bell on Tuesday.

Novo Nordisk’s trial enrolled 17,604 adults aged 45 years or older with overweight or obesity and established cardiovascular disease (CVD) with no prior history of diabetes.

“The trial achieved its primary objective by demonstrating a statistically significant and superior reduction in MACE of 20% for people treated with semaglutide 2.4 mg compared to placebo,” the company said in a press release.

Martin Holst Lange, executive vice president for development at Novo Nordisk, said that the results from this “landmark trial” have “demonstrated that semaglutide 2.4 mg has the potential to change how obesity is regarded and treated.”

The company will now file for regulatory approval in the U.S. and EU in 2023.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.